Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
GC Biopharma Corp (006280 KS)
Watchlist
115
Analysis
Health Care
•
South Korea
GC Biopharma is a biopharmaceutical company headquartered in Yongin, South Korea. It manufactures household medical drugs. The Company's product includes medicines for cold and fever, nutrition, antiseptic drug, and a lip balm.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
GC Biopharma Corp
•
06 Aug 2026 22:46
Primer: GC Biopharma Corp (006280 KS) - Aug 2026
GC Biopharma is poised for a significant earnings rebound in the second half of 2026, driven by the recognition of deferred revenues and strong...
αSK Primers
104 Views
Share
bullish
•
GC Biopharma Corp
•
25 Jul 2026 08:02
•
Broker
GC Biopharma (006280 KS/Buy)2Q26 Preview: Earnings Set to Improve in 2H
We expect GC Biopharma to post below-consensus 2Q26 results, with revenue of W418.7bn (-16.3% YoY; vs. consensus of W473.6bn) and operating profit...
Mirae Asset Securities
Follow
113 Views
Share
bullish
•
GC Biopharma Corp
•
14 May 2026 08:54
•
Broker
GC Biopharma (006280 KS) Alyglo Performance Beats Expectations
For 1Q26, GC Biopharma reported revenue of W435.5bn (+13.5% YoY) and operating profit of W11.7bn (+47% YoY), in line with market expectations.
Mirae Asset Securities
Follow
122 Views
Share
bullish
•
Thematic (Sector/Industry)
•
13 Sep 2026 08:30
APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
Tina Banerjee
Follow
96 Views
Share
bullish
•
Thematic (Sector/Industry)
•
06 Sep 2026 08:30
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
Tina Banerjee
Follow
103 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x